We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Journal Articles

in Myeloma

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Editorial  | 
Association of Agent Orange With Plasma Cell Disorder Further Evidence
Nikhil C. Munshi, MD
JAMA Oncology
Original Investigation  | 
Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance An Operation Ranch Hand Veteran Cohort Study
Ola Landgren, MD, PhD; Youn K. Shim, PhD; Joel Michalek, PhD; et al.
JAMA Oncology
Invited Commentary  | 
Multiple Myeloma—Better Drugs Ask for More Stringent Evaluations
Pieter Sonneveld, MD, PhD
JAMA Oncology
Original Investigation  | 
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde, MD; Mark Roschewski, MD; Adriana Zingone, MD, PhD; et al.